Trial Profile
PANTHER. A Randomized Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel (dtEC→dtT) Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel (FEC→T) in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary) ; Fluorouracil (Primary) ; Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms PANTHER; SOS
- 18 Dec 2019 Results assessing Efficacy and Safety of Tailored and Dose-Dense Adjuvant Chemotherapy and Trastuzumab for Resected HER2-Positive Breast Cancer published in the Cancer
- 24 Oct 2018 Results published in the Annals of Oncology
- 05 Jun 2018 Results assessing efficacy and safety presented at the 54th Annual Meeting of the American Society of Clinical Oncology